Hepatitis C Combination Therapy - Novelos Therapeutics Closes $15 Million Private Placement

Novelos Therapeutics Closes $15 Million Private Placement
[Press Release] Business Wire via Yahoo! Finance - Mar 07 5:03 PM
NEWTON, Mass.----March 7, 2006--Novelos Therapeutics, Inc. , a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, announced that today, it closed its previously announced private placement resulting in $15.06 million in gross proceeds through the sale of shares of its common stock and warrants to institutional investors.Save to My Web

Human Genome Sciences: Challenging the Pegylated Interferons
RedNova - Mar 15 11:32 AM
Interim results of a phase II trial of Human Genome Sciences' Albuferon in combination with ribavirin showed a significant antiviral effect in non-responders at 48 weeks of treatment.Save to My Web

ViRexx Announces Collaboration with Defence Research and Development Canada-Suffield to Expand Chimigen'TM' Platform
[Press Release] Business Wire via Yahoo! Finance - Mar 31 5:00 AM
EDMONTON, Alberta----March 31, 2006--ViRexx Medical Corp. , a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced that it has entered into a research collaboration with Defence Research and Development Canada - Suffield to carry out research on applying ViRexx's proprietary Chimigen vaccine platform for Save to My Web

Hepatitis C Victims 'Could Hit 1m'
RedNova - Mar 23 5:33 AM
THERE could be five times the number of people infected with hepatitis C than current estimates suggest, an expert warned yesterday.Save to My Web

NOVARTIS announces in-licensing of valopicitabine (NM283), a novel first-in- ...
Financial.de - Mar 28 11:21 PM
Basel, Switzerland, March 29, 2006 - Novartis ( News / Kurs / Chart / Board ) announced today that it has exercised its option from Idenix Pharmaceuticals to in-license the late-stage development compound valopicitabine (NM283) for the treatment of hepatitis C, a condition estimated to affect more than 170 million people worldwide and a major cause of liver disease.Save to My Web

XTL Biopharmaceuticals Ltd. Raises $28 Million in Private Equity Transaction With Institutional Investors
RedNova - Mar 20 3:01 AM
NEW YORK, March 20 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd.Save to My Web

Cuban combined therapy against chronic Hepatitis C
Granma Internacional - Mar 22 11:36 AM
A Cuban combination therapy for the treatment of chronic Hepatitis C is to be put on the market by the Heber Biotec S.A. company in Latin America, Asia, Africa, the Middle East and Europe, where this firm has registered the Heberon Alfa R (human recombinant Interferon lfa 2b).Save to My Web